市場調査レポート
商品コード
1430667

特発性肺線維症-世界の臨床試験レビュー(2024年)

Idiopathic Pulmonary Fibrosis - Global Clinical Trials Review, 2024

出版日: | 発行: GlobalData | ページ情報: 英文 454 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
特発性肺線維症-世界の臨床試験レビュー(2024年)
出版日: 2024年01月25日
発行: GlobalData
ページ情報: 英文 454 Pages
納期: 即納可能 即納可能とは
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、特発性肺線維症の臨床試験市場について調査し、市場の概要とともに、フェーズ別、試験状況別、エンドポイント別、スポンサータイプ別、地域別動向、主要企業、臨床試験プロファイルなどを提供しています。

目次

  • レポートガイダンス
  • 臨床試験調査範囲
  • 地域別臨床試験
  • 国別臨床試験と平均登録者数
  • アジア太平洋において臨床試験に貢献する主要5カ国
  • 欧州において臨床試験に貢献する主要5カ国
  • 北米において臨床試験に貢献する主要5カ国
  • 中東・アフリカにおいて臨床試験に貢献する主要5カ国
  • 中南米において臨床試験に貢献する主要5カ国
  • G7諸国別臨床試験:特発性肺線維症の呼吸器臨床試験に対する割合
  • G7諸国における臨床試験、フェーズ別
  • G7諸国における臨床試験、試験状況別
  • E7諸国別臨床試験:特発性肺線維症の呼吸器臨床試験に対する割合
  • E7諸国における臨床試験、フェーズ別
  • E7諸国における臨床試験、試験状況別
  • 臨床試験、フェーズ別
  • 進行中試験、フェーズ別
  • 臨床試験、試験状況別
  • 臨床試験、エンドポイントステータス別
  • 一定期間にわたって採用された被験者
  • 臨床試験、スポンサータイプ別
  • 著名なスポンサー
  • 特発性肺線維症治療薬の臨床試験に参加している主要企業
  • 主要な薬剤
  • 臨床試験プロファイルの概要

付録

  • 略語
  • 定義
  • 調査手法
  • 2次調査
  • GlobalDataについて
  • お問い合わせ
  • 情報源
図表

List of Tables

List of Tables

  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2024*
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
  • Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*

List of Figures

List of Figures

  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2024*
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2024*
  • Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2019-2023
  • Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2024*
  • Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2024*
  • GlobalData Methodology
目次

GlobalData's clinical trial report, "Idiopathic Pulmonary Fibrosis - Global Clinical Trials Review, 2024" provides an overview of Idiopathic Pulmonary Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Pulmonary Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Idiopathic Pulmonary Fibrosis to Respiratory Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Idiopathic Pulmonary Fibrosis Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source